Ranbaxy Laboratories’ German subsidiary - Basics Gmbh in Leverkusen, has launched Atorvastatin basics (10/20/40/80 mg), a generic version of the cholesterol lowering drug Sortis, in the German market.
The company, pursuant to a settlement agreement with Pfizer, has obtained the rights to an early entry of Atorvastatin in the German market. Pfizer’s patent for Sortis expires in Germany on May 7, 2012. Further, Basics’ affiliates in Germany, Daiichi Sankyo Deutschland Gmbh, are expected to assist the company in the launch.
Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.
